Menezes J, Jondal M, Leibold W, Dorval G
Infect Immun. 1976 Feb;13(2):303-10. doi: 10.1128/iai.13.2.303-310.1976.
In order to further understand Epstein-Barr virus (EBV)-lymphocyte interactions, we investigated a chain of events including: (i) EBV binding to human lymphocyte subpopulations; (ii) the earliest appearance of EBV-determined nuclear antigen (EBNA) in the lymphocytes after EBV infection; and (iii) establishment of continuous lymphoblastoid cell lines (LCL) by infecting with EBV different types of lymphocyte preparations from the same as well as from different donors. By using direct membrane immunofluorescence assay, we found that only a small fraction of human peripheral blood and cord blood lymphocytes (CBL), and possibly less than 31% of the T cell-depleted lymphocyte population, carry receptors for P3HR-1 strain of EBV. The number of cells carrying receptors for EBV did not vary considerably among different blood lymphocyte populations from several normal donors. EBV adsorption on lymphocyte subpopulations showed that purified thymus-dependent (T) cells and thymocytes did not adsorb EBV, in contrast to T cell-depleted lymphocyte populations and lymphoid cells from fetal liver and spleen. In CBL infected with EBV strain B95-8, EBNA was detected by anti-complement immunofluorescence as early as 18 h after infection. This indicates that EBNA is the earliest detectable EBV-determined intracellular antigen to appear after infection and before or during lymphocyte transformation by EBV. Transformation was observed only in lymphocyte cultures containing detectable thymus-independent B cells but not in cultures of purified T cells. With one exception (es-b-1), all the EBV-transformed LCL from different origins carried surface-bound immunoglobulins (a B cell marker). These included also the 10 LCL obtained by infecting cultures of adherent cells from different donors. With regard to its surface markers, ES-B-1 appeared to be an exceptional EBV genome-carrying line, and it also lacked the ability to form spontaneous rosettes with sheep erythrocytes (a T cell marker). Therefore, it is possible that ES-B-1 was derived from an atypical B cell or B cell precursor or from a so-called "null cell" transformed by EBV.
为了进一步了解爱泼斯坦 - 巴尔病毒（EBV）与淋巴细胞的相互作用，我们研究了一系列事件，包括：（i）EBV与人淋巴细胞亚群的结合；（ii）EBV感染后淋巴细胞中最早出现的EBV核抗原（EBNA）；以及（iii）用EBV感染来自同一供体以及不同供体的不同类型淋巴细胞制剂，建立连续淋巴母细胞系（LCL）。通过直接膜免疫荧光测定，我们发现只有一小部分人外周血和脐血淋巴细胞（CBL），以及可能不到31%的T细胞耗竭淋巴细胞群体携带EBV P3HR - 1株的受体。来自几个正常供体的不同血液淋巴细胞群体中携带EBV受体的细胞数量没有显著差异。EBV在淋巴细胞亚群上的吸附表明，纯化的胸腺依赖性（T）细胞和胸腺细胞不吸附EBV，这与T细胞耗竭的淋巴细胞群体以及来自胎儿肝脏和脾脏的淋巴细胞相反。在用EBV B95 - 8株感染的CBL中，早在感染后18小时就通过抗补体免疫荧光检测到了EBNA。这表明EBNA是感染后、EBV使淋巴细胞转化之前或期间最早可检测到的EBV决定的细胞内抗原。仅在含有可检测到的胸腺非依赖性B细胞的淋巴细胞培养物中观察到转化，而在纯化T细胞培养物中未观察到。除了一个例外（es - b - 1），所有来自不同来源的EBV转化的LCL都携带表面结合免疫球蛋白（一种B细胞标志物）。这还包括通过感染来自不同供体的贴壁细胞培养物获得的10个LCL。就其表面标志物而言，ES - B - 1似乎是一个特殊的携带EBV基因组的细胞系，并且它也缺乏与绵羊红细胞形成自发玫瑰花结的能力（一种T细胞标志物）。因此，ES - B - 1有可能源自非典型B细胞或B细胞前体，或者源自被EBV转化的所谓“裸细胞”。
